What Are the Levels of Wegovy and How Does the Dose Schedule Work?

You've just started Wegovy and your pen says 0.25 mg, is something missing?

Nothing is missing. The lowest level of Wegovy exists purely to settle your system rather than to drive weight loss. Most people starting the injection wonder why such a small amount would be prescribed, and the honest answer is: it's a safety measure. Semaglutide slows gastric emptying and reduces appetite through GLP-1 receptor activity in the gut and brain, and those mechanisms can cause nausea, vomiting or constipation if the dose rises too quickly. Starting at 0.25 mg gives your body roughly four weeks to adapt before moving to 0.5 mg.

At 0.5 mg, the adaptation continues. Some people notice a modest reduction in appetite at this stage; others feel little change. Both are normal. If you are curious about what levels of Wegovy are there from the very beginning of treatment, understanding each step in sequence can make the early weeks feel less uncertain. The key thing to watch at the lower levels is tolerability (how well your gut handles each step) because that information guides when and whether the prescriber moves you up. A simple habit worth building: note your appetite, energy and any GI symptoms on the same day each week. One minute of jotting helps your prescriber make a more informed call at your next review.

The semaglutide treatment overview covers how the medicine works at a biological level if you'd like more background before reading on.

Where the clinical effect actually builds: 1.0 mg, 1.7 mg and the 2.4 mg maintenance level

Once you reach 1.0 mg, the appetite-suppression effect becomes more pronounced for most people. Portion sizes that previously felt normal start to feel like too much, that fullness signal arrives earlier in a meal. Research from the STEP 1 trial, published in the New England Journal of Medicine, found that adults using semaglutide 2.4 mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks, compared with roughly 2.4% for placebo. That headline figure comes from people who reached and stayed on the maintenance dose, the lower levels are the pathway to get there, not the destination.

At 1.7 mg, many people find the appetite effects are already substantial. The move to 2.4 mg (the standard maintenance level) is still recommended by the prescriber unless tolerability is a problem, because the clinical evidence is strongest at that level. If side effects at any stage are significant, the prescriber may extend a level rather than push up on schedule. That flexibility is built into the design of the programme.

For a fuller picture of what the treatment involves from week one, the Wegovy treatment page covers the practical detail alongside the clinical evidence.

The newest level: Wegovy 7.2 mg and what it means for your options

On 14 April 2026, the MHRA approved a dedicated 7.2 mg single-dose Wegovy pen, the highest level available in the UK. This approval applies specifically to adults with a BMI of 30 or above; the cardiovascular indication uses different criteria. If you want to understand how many levels of Wegovy are there, including where 7.2 mg sits relative to all the others, that page walks through the full titration schedule from start to finish. It is not a different treatment, it is the same semaglutide at a higher maintenance dose, with trial data suggesting average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results. Full details of that approval are on the GOV.UK announcement from the MHRA.

Not everyone will need or be suitable for 7.2 mg. Prescribers consider the response at 2.4 mg, tolerability history and individual clinical picture. If you are considering whether this level might be relevant to you, that conversation belongs in a consultation, not on a box or a forum. Cost implications across the full titration schedule are worth understanding early, and our Wegovy cost guide breaks down what private treatment typically involves.

It is also worth noting that the NICE recommendation for semaglutide (TA875) sets specific criteria for NHS access, including a maximum treatment duration of two years within a specialist weight management service. Private routes have different parameters, your prescriber explains what applies to your situation. The full NICE guidance is at nice.org.uk/guidance/ta875.

What happens if you don't tolerate a level, or reach the top?

Tolerability issues are common and expected, particularly in the first few weeks at each new level. Nausea and loose stools are the most reported complaints; they typically ease within one to two weeks as the body adjusts. If they don't, the right move is to contact your prescribing team, not to delay or skip doses independently. The side effects guide covers the full picture, including what warrants urgent attention versus what is a normal part of starting treatment.

At the top of the dose ladder (whether that is 2.4 mg or, for some people, 7.2 mg) the focus shifts from titration to maintenance. At this stage, clinical reviews look at how much weight has been lost, whether lifestyle changes are embedded and whether continuing treatment is appropriate. NICE guidance notes that if less than 5% weight loss has occurred after six months on the highest tolerated maintenance dose, continuing should be reviewed with the prescriber. That is not a failure; it is a clinical signal that a different approach or medicine might serve better.

If you are weighing Wegovy against other treatment options, our weight-loss treatment overview sets out what is currently licensed in the UK and what each involves. And if you have specific questions, the FAQs page covers the queries our prescribers hear most often.